Oncorus Announces Pricing of Initial Public Offering
October 01 2020 - 7:11PM
Oncorus, Inc., a clinical stage biopharmaceutical company focused
on developing next-generation viral immunotherapies to transform
outcomes for cancer patients, today announced the pricing of its
initial public offering of 5,800,000 shares of common stock at a
price to the public of $15.00 per share. The gross proceeds to
Oncorus, before deducting underwriting commissions and offering
expenses, are expected to be approximately $87.0 million. All of
the shares of common stock are being offered by Oncorus. In
addition, Oncorus has granted the underwriters a 30-day option to
purchase up to 870,000 additional shares of common stock at the
initial public offering price less underwriting discounts and
commissions.
The shares are
expected to begin trading on the Nasdaq Global Select Market under
the ticker symbol “ONCR” on October 2, 2020, and the offering is
expected to close on or about October 6, 2020, subject to customary
closing conditions.
Jefferies, Evercore
ISI and Piper Sandler are acting as joint book-running managers for
the offering.A registration statement relating to the common stock
being sold in this offering has been filed with the U.S. Securities
and Exchange Commission and was declared effective on October 1,
2020. The offering of these shares is being made only by means of a
prospectus forming part of the effective registration statement
relating to these shares. Copies of the final prospectus, when
available, may be obtained from: Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, New York 10022, via telephone at (877) 821-7388 or via email
at Prospectus_Department@Jefferies.com; Evercore Group L.L.C.,
Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor,
New York, New York 10055, by telephone at 888-474-0200, or by email
at ecm.prospectus@evercore.com; Piper Sandler & Co., Attention:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis,
Minnesota 55402, via telephone at (800) 747-3924 or via email at
prospectus@psc.com.
This press release
shall not constitute an offer to sell or the solicitation of an
offer to buy these securities, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About
OncorusOncorus is a clinical stage biopharmaceutical
company focused on developing next-generation viral immunotherapies
to transform outcomes for cancer patients. Using its two distinct
proprietary platforms, the Company is developing a pipeline of
intratumorally and intravenously administered product candidates
designed to selectively attack and kill tumor cells and stimulate
multiple arms of the immune system against tumors. Oncorus’ lead
product candidate, ONCR-177, is an intratumorally administered
viral immunotherapy based on its oncolytic HSV-1 platform, referred
to as the oHSV Platform, which leverages the Herpes Simplex Virus
type 1, or HSV-1, a virus which has been clinically proven to
effectively treat certain cancers.
Forward-Looking Statements
This press release
contains certain forward-looking statements, including statements
with regard to the timing and completion of Oncorus’ proposed
initial public offering and its expectations regarding the
commencement of trading on the Nasdaq Global Market. Words such as
"anticipates," "believes," "expects," "intends," "projects,"
"anticipates," and "future" or similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are subject to the inherent uncertainties in predicting
future results and conditions and no assurance can be given that
the proposed initial public offering discussed above will be
consummated on the terms described or at all. Completion of the
proposed initial public offering and the terms thereof are subject
to numerous factors, many of which are beyond the control of
Oncorus, including, without limitation, market conditions, failure
of customary closing conditions and the risk factors and other
matters set forth in Oncorus’ filings with the Securities and
Exchange Commission. Oncorus undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
Media Contact:
Liz Melonemedia@oncorus.com
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jul 2023 to Jul 2024